ContributorsPublishersAdvertisers

Newly Approved Treatment Shows Promise for Advanced Cervical Cancer

Cancer Health
Cancer Health
 2021-09-24
Cover picture for the article

On September 20, the Food and Drug Administration (FDA) granted accelerated approval of Tivdak (tisotumab vedotin), an antibody-drug conjugate for the treatment of recurrent or metastatic cervical cancer that has progressed despite chemotherapy. In a Phase II clinical trial, Tivdak used as monotherapy led to complete or partial remission...

www.cancerhealth.com

Comments / 0

Comments / 0